Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KRYS – Krystal Biotech, Inc.

Krystal Biotech, Inc.
KRYS
$138.88
Name : Krystal Biotech, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $4,013,451,520.00
EPSttm : 4.17
finviz dynamic chart for KRYS
Krystal Biotech, Inc.
$138.88
2.60%
$3.70

Float Short %

12.23

Margin Of Safety %

43

Put/Call OI Ratio

1.26

EPS Next Q Diff

0.21

EPS Last/This Y

2.76

EPS This/Next Y

5.08

Price

138.96

Target Price

205.2

Analyst Recom

1.18

Performance Q

-24.01

Relative Volume

1.12

Beta

0.68

Ticker: KRYS




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02KRYS125.350.791.338595
2025-06-03KRYS131.040.790.968624
2025-06-04KRYS132.120.805.358819
2025-06-05KRYS132.820.990.999863
2025-06-06KRYS136.951.190.1710872
2025-06-09KRYS136.081.190.0310930
2025-06-10KRYS138.471.200.0110922
2025-06-11KRYS139.731.200.0210931
2025-06-12KRYS140.51.18999.9911051
2025-06-13KRYS137.161.180.0111051
2025-06-16KRYS133.041.160.5811160
2025-06-17KRYS130.021.160.0711162
2025-06-18KRYS132.151.151.0011170
2025-06-20KRYS132.511.150.5811192
2025-06-23KRYS138.051.260.1410245
2025-06-24KRYS143.71.260.3710270
2025-06-25KRYS142.51.260.2410285
2025-06-26KRYS142.691.260.0010291
2025-06-27KRYS138.831.260.0210291
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02KRYS125.2235.277.45.88
2025-06-03KRYS130.9135.290.15.88
2025-06-04KRYS132.1135.281.25.88
2025-06-05KRYS132.6235.279.95.88
2025-06-06KRYS136.8135.286.65.88
2025-06-09KRYS136.0835.277.35.88
2025-06-10KRYS138.3035.282.95.88
2025-06-11KRYS139.6735.281.55.88
2025-06-12KRYS140.3335.280.15.88
2025-06-13KRYS137.1035.273.15.88
2025-06-16KRYS133.0635.271.55.88
2025-06-17KRYS130.0935.273.25.88
2025-06-18KRYS132.0935.282.95.88
2025-06-20KRYS132.4635.279.55.88
2025-06-23KRYS138.0235.289.45.88
2025-06-24KRYS143.9135.289.75.88
2025-06-25KRYS142.4635.276.75.88
2025-06-26KRYS142.5735.279.05.88
2025-06-27KRYS138.9635.272.55.88
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02KRYS-4.68-1.2710.48
2025-06-03KRYS-4.68-1.2710.48
2025-06-04KRYS-4.68-1.2710.48
2025-06-05KRYS-4.68-1.2710.48
2025-06-06KRYS-4.68-1.2710.48
2025-06-09KRYS-4.68-1.2810.48
2025-06-10KRYS-4.68-1.2810.48
2025-06-11KRYS-4.68-1.2811.77
2025-06-12KRYS-4.68-1.2811.77
2025-06-13KRYS-4.68-1.2811.77
2025-06-16KRYS-2.41-1.3011.77
2025-06-17KRYS-2.41-1.3011.77
2025-06-18KRYS-2.41-1.3011.77
2025-06-20KRYS-2.41-1.3011.77
2025-06-23KRYS-2.41-1.3311.77
2025-06-24KRYS-2.41-1.3311.77
2025-06-25KRYS-2.41-1.3311.77
2025-06-26KRYS-2.41-1.3312.23
2025-06-27KRYS-2.41-1.3312.23
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

1.2

Avg. EPS Est. Current Quarter

1.26

Avg. EPS Est. Next Quarter

1.41

Insider Transactions

-2.41

Institutional Transactions

-1.33

Beta

0.68

Average Sales Estimate Current Quarter

95

Average Sales Estimate Next Quarter

105

Fair Value

198.92

Quality Score

87

Growth Score

44

Sentiment Score

53

Actual DrawDown %

36.7

Max Drawdown 5-Year %

-53.4

Target Price

205.2

P/E

33.45

Forward P/E

15.93

PEG

0.54

P/S

12.04

P/B

4.08

P/Free Cash Flow

31.03

EPS

4.15

Average EPS Est. Cur. Y​

5.88

EPS Next Y. (Est.)

10.95

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

37.18

Relative Volume

1.12

Return on Equity vs Sector %

-11.3

Return on Equity vs Industry %

6.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-1.7

EBIT Estimation

72.5
Krystal Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 275
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today
news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance
stock history KRYS – Krystal Biotech, Inc. invest stock market
stock prices KRYS premarket after hours
ticker KRYS fair value insiders trading